2C-AL, also known as 4-allyl-2,5-dimethoxyphenethylamine, is a drug from the substituted phenethylamine family which acts as an agonist of the 5-HT2A receptor, with an of 2.15nM at 5-HT2A vs. 77.71nM at 5-HT2B, and produces a head-twitch response in animal studies. It was first discussed as a hypothetical compound in Daniel Trachsel's 2013 review of the field after his successful synthesis of the related compounds 2C-V and 2C-YN, and finally synthesised by a team at Gilgamesh Pharmaceuticals in 2020 using a different synthetic route from that employed by Trachsel.Patentscope. PHENALKYLAMINES AND METHODS OF TREATING MOOD DISORDERS. Patent WO/2022/006186. Retrieved 2026-06-18 It is a controlled substance in Canada under phenethylamine blanket-ban language.
See also 2C (psychedelics) 2C-CP 2C-IP 2C-P 2C-T-16 2C-T-TFM Allylescaline 3C-AL
References
External links 2C-AL - Isomer Design